BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//NextToU//EN
CALSCALE:GREGORIAN
BEGIN:VEVENT
UID:fe2317f6-b26a-49cc-9cf0-beea04eb5a7d@nexttoyou
DTSTAMP:20261106T165954Z
DTSTART:20261123T200000Z
DTEND:20261123T210000Z
SUMMARY:Cancer Therapeutics Training (CT2) Talk | Thomas Molley\, PhD
LOCATION:Comer Commons
DESCRIPTION:Pairing Embolic Exclusion with Prodrug Generation for Treatmen
 t of Hypervascular Tumors\n\nThomas Molley\, PhD\nChief Executive Officer
  & Co-Founder\nOxyLo\n\nTom is a materials scientist and bioengineer work
 ing across hydrogel design\, enzyme engineering\, bioprinting\, and stem-
 cell-derived tissue models. He completed his PhD at UNSW Sydney in 2022\,
  and was an F32 postdoctoral researcher in the Engler Lab at UC San Diego
  from 2023 to 2025. In 2024\, Tom co-founded OxyLo as the CEO\, a San Die
 go biotech that builds enzyme-based technologies for controlling oxygen a
 nd drug production in the cellular microenvironment. He invented the comp
 any’s core enzyme-microcapsule platform and prodrug development system th
 at underpins the locoregional cancer therapy in development.\n\nhttp://ne
 xt-to-u.app/events/fe2317f6-b26a-49cc-9cf0-beea04eb5a7d
URL:http://next-to-u.app/events/fe2317f6-b26a-49cc-9cf0-beea04eb5a7d
END:VEVENT
END:VCALENDAR